Cargando…
In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance
An epidemic of avian type H7N9 influenza virus, which took place in China in 2013, was enhanced by a naturally occurring R294K mutation resistant against Oseltamivir at the catalytic site of the neuraminidase. To cope with such drug-resistant neuraminidase mutations, we applied the molecular docking...
Autores principales: | Sarukhanyan, Edita, Shanmugam, Tipack Ayothyapattanam, Dandekar, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503969/ https://www.ncbi.nlm.nih.gov/pubmed/36144655 http://dx.doi.org/10.3390/molecules27185920 |
Ejemplares similares
-
Peramivir for influenza
Publicado: (2019) -
In Silico Designed Axl Receptor Blocking Drug Candidates
Against Zika Virus Infection
por: Sarukhanyan, Edita, et al.
Publicado: (2018) -
Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020) -
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K
por: Tran-To Su, Chinh, et al.
Publicado: (2013) -
Safety and efficacy of peramivir for influenza treatment
por: Hata, Atsuko, et al.
Publicado: (2014)